Conatus Pharmaceuticals Inc. (CNAT) announced after the bell Monday that it has entered into an exclusive option, collaboration and license agreement with Novartis to develop and commercialize emricasan.
from RTT - Before the Bell http://ift.tt/2hSV6Ds
via IFTTT
No comments:
Post a Comment